BidaskClub downgraded shares of Healthequity (NASDAQ:HQY) from a hold rating to a sell rating in a research note published on Saturday morning, BidAskClub reports.

Other equities analysts have also issued reports about the stock. TheStreet lowered shares of Healthequity from a b rating to a c+ rating in a report on Tuesday, September 3rd. Wells Fargo & Co lowered their target price on shares of Healthequity from $80.00 to $76.00 and set an outperformer rating for the company in a report on Wednesday, September 4th. ValuEngine cut shares of Healthequity from a buy rating to a hold rating in a research report on Tuesday, August 6th. Bank of America set a $79.00 target price on shares of Healthequity and gave the company a buy rating in a research report on Wednesday, September 4th. Finally, Citigroup reissued a buy rating on shares of Healthequity in a research note on Friday, June 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Healthequity presently has a consensus rating of Buy and a consensus price target of $81.00.

Shares of NASDAQ:HQY opened at $59.94 on Friday. The company has a current ratio of 22.98, a quick ratio of 15.59 and a debt-to-equity ratio of 0.04. Healthequity has a 1-year low of $50.29 and a 1-year high of $101.58. The stock has a market capitalization of $3.76 billion, a P/E ratio of 63.09, a P/E/G ratio of 3.00 and a beta of 1.56. The business has a 50-day moving average price of $67.54 and a two-hundred day moving average price of $70.74.

Healthequity (NASDAQ:HQY) last issued its earnings results on Tuesday, September 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.10. Healthequity had a net margin of 28.13% and a return on equity of 11.77%. The company had revenue of $86.60 million for the quarter, compared to analyst estimates of $85.33 million. During the same quarter last year, the firm earned $0.36 EPS. The company’s revenue for the quarter was up 21.8% on a year-over-year basis. As a group, equities analysts predict that Healthequity will post 0.93 EPS for the current year.

In other Healthequity news, CEO Jon Kessler purchased 10,000 shares of the company’s stock in a transaction dated Friday, July 12th. The shares were bought at an average price of $61.00 per share, with a total value of $610,000.00. Following the completion of the transaction, the chief executive officer now directly owns 442,410 shares in the company, valued at approximately $26,987,010. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Angelique Christine Hill sold 9,500 shares of the firm’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $71.40, for a total value of $678,300.00. Following the sale, the vice president now directly owns 15,887 shares in the company, valued at approximately $1,134,331.80. The disclosure for this sale can be found here. Insiders have sold a total of 37,899 shares of company stock worth $2,751,451 in the last three months. 3.70% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the company. Jackson Square Partners LLC acquired a new stake in shares of Healthequity in the 1st quarter valued at about $128,524,000. BlackRock Inc. boosted its position in shares of Healthequity by 13.1% during the second quarter. BlackRock Inc. now owns 7,268,685 shares of the company’s stock worth $475,373,000 after buying an additional 840,177 shares during the period. Renaissance Technologies LLC boosted its position in shares of Healthequity by 76.8% during the second quarter. Renaissance Technologies LLC now owns 1,162,234 shares of the company’s stock worth $76,010,000 after buying an additional 504,700 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of Healthequity during the second quarter worth about $30,550,000. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Healthequity by 1,745.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 476,201 shares of the company’s stock worth $31,144,000 after buying an additional 450,402 shares in the last quarter. Institutional investors and hedge funds own 94.77% of the company’s stock.

About Healthequity

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Read More: How a Back-End Load Mutual Fund Works

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.